Literature DB >> 26130867

Efficacy and Safety of Canagliflozin as Add-On Therapy to Metformin in Type 2 Diabetes.

Dawn M Battise.   

Abstract

Entities:  

Year:  2014        PMID： 26130867      PMCID： PMC4485248          DOI： 10.2337/diaclin.32.2.81

Source DB:  PubMed          Journal:  Clin Diabetes        ISSN： 0891-8929


× No keyword cloud information.
  12 in total

1.  Deteriorating beta-cell function in type 2 diabetes: a long-term model.

Authors:  A Bagust; S Beale
Journal:  QJM       Date:  2003-04

Review 2.  Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

Authors:  Muhammad A Abdul-Ghani; Luke Norton; Ralph A Defronzo
Journal:  Endocr Rev       Date:  2011-05-23       Impact factor: 19.871

Review 3.  Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.

Authors:  Joshua J Neumiller; John R White; R Keith Campbell
Journal:  Drugs       Date:  2010-03-05       Impact factor: 9.546

4.  Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.

Authors:  Jan Bolinder; Östen Ljunggren; Joel Kullberg; Lars Johansson; John Wilding; Anna Maria Langkilde; Jennifer Sugg; Shamik Parikh
Journal:  J Clin Endocrinol Metab       Date:  2012-01-11       Impact factor: 5.958

5.  Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.

Authors:  J Jendle; M A Nauck; D R Matthews; A Frid; K Hermansen; M Düring; M Zdravkovic; B J Strauss; A J Garber
Journal:  Diabetes Obes Metab       Date:  2009-12       Impact factor: 6.577

6.  Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.

Authors:  Bruce Neal; Vlado Perkovic; Dick de Zeeuw; Kenneth W Mahaffey; Greg Fulcher; Peter Stein; Mehul Desai; Wayne Shaw; Joel Jiang; Frank Vercruysse; Gary Meininger; David Matthews
Journal:  Am Heart J       Date:  2013-06-24       Impact factor: 4.749

7.  American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary.

Authors:  Alan J Garber; Martin J Abrahamson; Joshua I Barzilay; Lawrence Blonde; Zachary T Bloomgarden; Michael A Bush; Samuel Dagogo-Jack; Michael B Davidson; Daniel Einhorn; W Timothy Garvey; George Grunberger; Yehuda Handelsman; Irl B Hirsch; Paul S Jellinger; Janet B McGill; Jeffrey I Mechanick; Paul D Rosenblit; Guillermo E Umpierrez; Michael H Davidson
Journal:  Endocr Pract       Date:  2013 May-Jun       Impact factor: 3.443

Review 8.  Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2012-04-19       Impact factor: 19.112

9.  Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.

Authors:  J-F Yale; G Bakris; B Cariou; D Yue; E David-Neto; L Xi; K Figueroa; E Wajs; K Usiskin; G Meininger
Journal:  Diabetes Obes Metab       Date:  2013-03-28       Impact factor: 6.577

10.  Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.

Authors:  Guntram Schernthaner; Jorge L Gross; Julio Rosenstock; Michael Guarisco; Min Fu; Jacqueline Yee; Masato Kawaguchi; William Canovatchel; Gary Meininger
Journal:  Diabetes Care       Date:  2013-04-05       Impact factor: 19.112
View more
  3 in total

1.  Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.

Authors:  Carol H Wysham; Patrick Lefebvre; Dominic Pilon; Mike Ingham; Marie-Hélène Lafeuille; Bruno Emond; Rhiannon Kamstra; Wing Chow; Michael Pfeifer; Mei Sheng Duh
Journal:  BMC Endocr Disord       Date:  2017-06-08       Impact factor: 2.763

2.  Health care provider experience with canagliflozin in real-world clinical practice: favorability, treatment patterns, and patient outcomes.

Authors:  Susan C Bolge; Natalia M Flores; Shu Huang; Jennifer Cai
Journal:  Int J Gen Med       Date:  2017-06-23

3.  Efficacy and Safety of Canagliflozin 300 mg in Overweight and Obese Type 2 Diabetes Mellitus Patients in a Real-world Setting: COLOR Study.

Authors:  Pankaj Aneja; Gaurav Bhalla; Neeti Parvesh; Kunal Aneja; Kashish Aneja
Journal:  Indian J Endocrinol Metab       Date:  2019 May-Jun
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.